Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes

A high-efficiency, low-toxicity, phospholipids-based phase separation gel for long-term delivery of peptides

(2015) Ting Zhang et al.   BIOMATERIALS

Characterization of the gila monster (Heloderma suspectum suspectum) venom proteome

(2015) Kristian W. Sanggaard et al.   Journal of Proteomics

A smart insulin patch

(2015) Omid Veiseh et al.   NATURE

Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification

(2014) Feng Qi et al.   Acta Biomaterialia

In situ gelling polyvalerolactone-based thermosensitive hydrogel for sustained drug delivery

(2014) Gyan P. Mishra et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A Novel Doxorubicin-Loaded in Situ Forming Gel Based High Concentration of Phospholipid for Intratumoral Drug Delivery

(2014) Wenqi Wu et al.   MOLECULAR PHARMACEUTICS

Global diets link environmental sustainability and human health

(2014) David Tilman et al.   NATURE

Fluorescent Exendin-4 Derivatives for Pancreatic β-Cell Analysis

(2013) Susan M. Clardy et al.   BIOCONJUGATE CHEMISTRY

Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus

(2013) Jae Yeon Kim et al.   BIOMATERIALS

A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel

(2013) Kun Li et al.   BIOMATERIALS

Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability

(2013) Feng Qi et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Injectable implants for the sustained release of protein and peptide drugs

(2013) Priyanka Agarwal et al.   DRUG DISCOVERY TODAY

Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres

(2013) Rongcai Liang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Once-Weekly Exenatide: An Extended-Duration Glucagon-Like Peptide Agonist for the Treatment of Type 2 Diabetes Mellitus

(2013) Molly G. Minze et al.   PHARMACOTHERAPY

Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats

(2012) Xin-gang Li et al.   ACTA PHARMACOLOGICA SINICA

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

In situ forming implants — an attractive formulation principle for parenteral depot formulations

(2012) Sabine Kempe et al.   JOURNAL OF CONTROLLED RELEASE

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent

(2010) Brian L. Furman   TOXICON

Goals of Treatment for Type 2 Diabetes:  -Cell preservation for glycemic control

(2009) P. Marchetti et al.   DIABETES CARE

Diagnosis and Classification of Diabetes Mellitus

(2009)   DIABETES CARE

Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats

(2009) Hyun-Hee Kwak et al.   PHARMACEUTICAL RESEARCH

Recent advances and challenges in designing stimuli-responsive polymers

(2009) Fang Liu et al.   PROGRESS IN POLYMER SCIENCE

Correlation of in vivo and in vitro release data for rh-INFα lipid implants

(2008) M. Schwab et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus

(2007) Michael E. Minshall et al.   VALUE IN HEALTH